Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Gross Margin for 5 consecutive years, with 89.64% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 424.0% year-over-year to 89.64%, compared with a TTM value of 88.54% through Dec 2025, up 293.0%, and an annual FY2025 reading of 88.54%, up 293.0% over the prior year.
  • Gross Margin was 89.64% for Q4 2025 at Kiniksa Pharmaceuticals International, up from 88.8% in the prior quarter.
  • Across five years, Gross Margin topped out at 123.46% in Q4 2021 and bottomed at 81.35% in Q2 2022.
  • Average Gross Margin over 5 years is 91.11%, with a median of 88.51% recorded in 2023.
  • The sharpest move saw Gross Margin crashed -1894bps in 2022, then soared 1209bps in 2023.
  • Year by year, Gross Margin stood at 123.46% in 2021, then dropped by -15bps to 104.52% in 2022, then dropped by -15bps to 88.51% in 2023, then dropped by -4bps to 85.4% in 2024, then grew by 5bps to 89.64% in 2025.
  • Business Quant data shows Gross Margin for KNSA at 89.64% in Q4 2025, 88.8% in Q3 2025, and 88.14% in Q2 2025.